XR5118, a novel modulator of plasminogen activator inhibitor-1 (PAI-1 ), increases endogenous tPA activity in the rat

Fibrinolysis and Proteolysis

Volumn 11, Issue 1, 1997, Pages 51-56

  Charlton, P ^a   Faint, R ^a   Barnes, C ^a   Bent, F ^a   Folkes, A ^b   Templeton, D ^b   Mackie, I ^b   Machin, S ^b   Bevan, P ^b  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; XR 5118;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FIBRINOLYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOSIS;

EID: 0030904328     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80009-4     Document Type: Article

References (22)

1. Van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 1995; 9: 263-276.
2. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957-15960.
3. Sancho E, Declerck P J, Price N C, Kelly S M, Booth N A. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate and cleaved forms. Biochemistry 1995; 34: 1064-1069.
4. Krishnamurti C, Alving B M. Plasminogen activator inhibitor type 1 : biochemistry and evidence for modulation of fibrinolysis in vivo. Sem Thromb Hemost 1992; 18: 67-80.
5. Torr-Brown S R, Sobel B E. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. ThrombRes 1993; 72: 413-421.
6. Stringer H A, Van Swieten P, Heijnen H F G, Sixma J J, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Arterioscler Thromb 1994; 14: 1452-1458.
7. Erickson L A, Fici G J, Lund J E, Boyle T P, Polites H G, Marotti K R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-76.
8. Carmeliet P, Strassen J M, Schoonjans L, Ream B, Van De Oord J J, De Mol M, Mulligan R C, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-2760.
9. Patrassi G M, Sartori M T, Saggiorato G, Boeri G, Girolami A. Familial thrombophilia associated with high levels of plasminogen activator inhibitor. Fibrinolysis 1992; 6: 99-103.
10. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992; 95: 105-117.
11. Aznar J, Estellés A. Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases. Haemostasis 1994; 24: 243-251.
12. Gray R P, Yudkin J S, Patterson L. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. Br Heart J 1993; 69: 228-232.
13. Abrahamsson T, Nerme V, Strömqvist M, Åkerblom B, Legnehed A, Pettersson K, Westin Eriksson A. Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin. Thromb Haemost 1996; 75: 118-126.
14. Levi M, Biemond B J, Van Zonneveld A-J, Ten Gate J W, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-312.
15. Biemond B J, Levi M, Coronel R, Janse M J, Ten Gate J W, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Circulation 1995; 91: 1175-1181.
16. Charlton P A, Faint R F, Bent F, Bryans J, Chicarelli-Robinson I, Mackie I, Machin S, Bevan P. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost 1996; 75: 808-815.
17. Serizawa K, Uranto T, Kozima Y, Takada Y, Takaka A. The potential role of platelet PAI-1 in tPA-mediated clot lysis of platelet rich plasma. Thromb Res 1993; 71: 289-300.
18. Ehnebom J, Kristianssen C, Björquist P, Deinum J, Boström S. A clot lysis assay to study the effect of PAI-1 on fibrinolysis. Thromb Haemost 1993; 69: 1330a.
19. Rânby M, Sundell I B, Nilsson T K. Blood collection in strong acidic anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 1989; 62: 917-922.
20. Hladovec J. Experimental arterial thrombosis in rats with continuous registration. Thromb Diath Haemostr 1971; 26: 407-410.
21. MacCallum P K, Meade T W, Howath D J. Determinants of the dilute whole blood clot lysis time (DCLT). Brit J Haemotol 1995; 89(Suppl 1): 28a.
22. Eitzman D T, Fay W P, Lawrence D A, Francis-Chmura A M, Shore J D, Olsen S T, Ginsburg D. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 1995; 95: 2416-2420.